No Data
Trending Industry Today: PHARMARON Leads Losses In CRO Stocks
WUXI BIO has once again passed the Japan PMDA GMP inspection, accumulating 42 passes through Global Pharmaceutical regulatory inspections.
WUXI BIO announced on February 27, 2025, in Wuxi / PR Newswire / -- that the company’s biopharmaceutical raw material production plants (MFG2 and MFG5) at its Wuxi base have again passed the GMP inspection by the Japan Pharmaceutical and Medical Devices Agency (PMDA). The company achieved a zero-defect result in this on-site inspection covering facility quality systems and the entire production process, showcasing its outstanding capability to meet Global regulatory requirements. So far, WUXI BIO has successfully accumulated.
WuXi Biologics Again Passed GMP Inspection by Japan PMDA
Is Trump’s risk disturbing the market? Pharmaceutical stocks have suddenly changed, and the WuXi group has collapsed entirely!
Under the AI boom, the Biomedical and AI Medical stocks have been running wild this year.
Trending Industry Today: WUXI BIO Leads Losses In CRO Stocks
The CRO Sector is under pressure, WUXI BIO (02269) fell 6.73% as it is rumored that the USA intends to restrict investments by Chinese enterprises in several strategic areas.
Kingwu Financial News | The CRO Sector is under pressure, WUXI BIO (02269) fell by 6.73%, WUXI APPTEC (02359) fell by 5.57%, VIVA BIOTECH (01873) fell by 3.77%, TIGERMED (03347) fell by 3.5%, PHARMARON (03759) fell by 3.12%. According to media reports citing anonymous USA officials, President Trump signed an order directing the Treasury Department's Committee on Foreign Investment in the USA (CFIUS) to continue restricting Chinese companies from making investments in several strategic sectors in the USA. Reports indicate that the purpose of the memorandum is to ensure USA National Security while requiring
